NewsRx Logo Login/Signup
Home Newsletters Products Library About Us Contact -- Search NewsRx

NewsRx | Free Trials
Advertisement
VerticalNews | Global Warming
NewsRx | Free Newsletters
 
----------
------------
NewsRx on Facebook
-----
NewsRx Passes
Press Release Submissions
PR Login
-----
2008 Award Logo
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
-----
Google 2009 PageRank: #2 Among Top Health News and Media Publications
Google 2009 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2009 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2009 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.

Security by Verisign

Search Results for SCOLR Pharma Inc


Filter Articles: Clinical News | Consumer News | Business News | All News | More Options

Results 1 - 20      Next >


Refine Search
Display Mode: Context | Summary
FDA Issues Complete Response Letter to SCOLR Pharma's Abbreviated New Drug Application for CDT(R) 12-Hour Pseudoephedrine
2009 FEB 2 ... Therapy, Treatment, U.S. Food and Drug Administration, Vasoconstrictor Agent, Scolr Pharma Inc. This article was prepared by Biotech Business Week editors from staff ...
Subject: Drug Development
Price: $3.00
*
SCOLR Pharma, Inc. Announces Appointment of Bruce S. Morra, Ph.D., as President & CEO
2009 FEB 16 ... SCOLR Pharma, Inc. (NYSE Alternext US: DDD) announced that the board of directors has ...
Subject: Scolr Pharma, Inc.
Price: $3.00
*
SCOLR Pharma, Inc. Announces Engagement of HealthPro as Financial Advisor
2009 APR 14 ... will result in any specific transactions. Keywords: Pharmaceuticals, Scolr Pharma Inc. This article was prepared by Drug Law Weekly editors from staff and ...
Subject: Scolr Pharma, Inc.
Price: $3.00
*
SCOLR Pharma, Inc. Appoints Stephen J. Turner as CEO
2009 SEP 14 ... forward." Keywords: Drugs, Ibuprofen, Pharmaceuticals, Therapy, Treatment, Scolr Pharma Inc. This article was prepared by Biotech Business Week editors from staff and ...
Subject: Pharmaceuticals
Price: $3.00
*
SCOLR Pharma, Inc. Receives Notice from NYSE Amex LLC Regarding Compliance Plan and Listing Standards
2009 OCT 6 ... with all applicable continued listing standards. Keywords: Pharmaceuticals, Scolr Pharma Inc. This article was prepared by Drug Law Weekly editors from staff and other ...
Subject: Pharmaceuticals
Price: $3.00
*
SCOLR Pharma, Inc. Receives Notice of Non-Compliance from NYSE Amex for Continued Listing Requirements
2009 SEP 15 ... Investment, Finance, Investing, Stock Market, Stock Trading, Pharmaceuticals, SCOLR Pharma Inc. This article was prepared by Drug Law Weekly editors from staff and other ...
Subject: SCOLR Pharma, Inc.
Price: $3.00
*
SCOLR Pharma, Inc. Reports First Quarter 2009 Financial Results
2009 MAY 11 ... Pseudoephedrine, Sympathomimetic, Therapy, Treatment, Vasoconstrictor Agent, Scolr Pharma Inc. This article was prepared by Biotech Business Week editors from staff ...
Subject: Scolr Pharma, Inc.
Price: $3.00
*
SCOLR Pharma, Inc. Reports Fourth Quarter 2008 Financial Results
2009 MAR 23 ... Therapy, Treatment, U.S. Food and Drug Administration, Vasoconstrictor Agent, Scolr Pharma Inc. This article was prepared by Biotech Business Week editors from staff ...
Subject: Pharmaceuticals
Price: $3.00
*
SCOLR Pharma, Inc. Reports Second Quarter 2009 Financial Results
2009 AUG 17 ... Pseudoephedrine, Sympathomimetic, Therapy, Treatment, Vasoconstrictor Agent, Scolr Pharma Inc. This article was prepared by Biotech Business Week editors from staff and ...
Subject: Pharmaceuticals
Price: $3.00
*
SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results
2009 NOV 23 ... Ibuprofen, Marketing and Licensing Agreements, Pharmaceuticals, Therapy, Treatment, Scolr Pharma Inc. This article was prepared by Biotech Business Week editors from staff and ...
Subject: Pharmaceuticals
Price: $3.00
*
SCOLR Pharma Announces Completion of Patient Enrollment and Dosing for Pivotal Clinical Trial Evaluating Extended Release Ibuprofen
2008 OCT 20 ... SCOLR Pharma, Inc. (AMEX: DDD) announced the completion of patient enrollment and dosing for ...
Subject: Scolr Pharma, Inc.
Price: $3.00
*
SCOLR Pharma's ANDA for 12-Hour CDT-Based Pseudoephedrine Accepted for Review by U.S. FDA
2008 OCT 6 ... Therapy, Treatment, U.S. Food and Drug Administration, Vasoconstrictor Agent, Zyrtec, Scolr Pharma Inc. This article was prepared by Biotech Business Week editors from staff ...
Subject: Regulatory Actions
Price: $3.00
*
SCOLR Pharma, Inc. Announces Positive Top-Line Results From Pivotal Clinical Trial Evaluating Efficacy of Extended-Release Ibuprofen
2008 NOV 17 ... SCOLR Pharma, Inc. (AMEX: DDD) reported favorable top-line results from its pivotal Phase III ...
Subject: Scolr Pharma, Inc.
Price: $3.00
*
SCOLR Pharma, Inc. Announces Resignation of CEO Daniel O. Wilds
2008 DEC 29 ... SCOLR Pharma, Inc. (NYSE Alternext: DDD) announced that Daniel O. Wilds had resigned as Chief ...
Subject: Scolr Pharma, Inc.
Price: $3.00
*
SCOLR Pharma, Inc. Receives $3.1 Million Lease Termination Payment
2008 OCT 6 ... needs." Keywords: Marketing and Licensing Agreements, Pharmaceuticals, Scolr Pharma Inc. This article was prepared by Biotech Business Week editors from staff ...
Subject: Marketing and Licensing Agreements
Price: $3.00
*
SCOLR Pharma, Inc. Reports Second Quarter 2008 Financial Results
2008 AUG 18 ... Regulatory Actions, Sympathomimetic, Therapy, Treatment, Vasoconstrictor Agent, Scolr Pharma Inc. This article was prepared by Biotech Business Week editors from staff ...
Subject: Drug Development
Price: $3.00
*
SCOLR Pharma, Inc. Reports Third Quarter 2008 Financial Results
2008 NOV 17 ... Therapy, Treatment, U.S. Food and Drug Administration, Vasoconstrictor Agent, Scolr Pharma Inc. This article was prepared by Biotech Business Week editors from staff ...
Subject: Scolr Pharma, Inc.
Price: $3.00
*
SCOLR Pharma, Inc. Submits Abbreviated New Drug Application for a 12-hour CDT-based Pseudoephedrine Formulation
2008 AUG 18 ... Regulatory Actions, Sympathomimetic, Therapy, Treatment, Vasoconstrictor Agent, Zyrtec, Scolr Pharma Inc. This article was prepared by Biotech Business Week editors from staff ...
Subject: Drug Development
Price: $3.00
*
SCOLR Pharma, Inc. to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
2008 NOV 18 ... SCOLR Pharma, Inc. (AMEX: DDD) announced that the Company will present at the Rodman & Renshaw ...
Subject: Scolr Pharma, Inc.
Price: $3.00
*

Results 1 - 20      Next >




-----------------------
PR Login